Symbols / ADMA
ADMA Chart
About
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.73B |
| Enterprise Value | 3.72B | Income | 209.45M | Sales | 488.56M |
| Book/sh | 1.81 | Cash/sh | 0.26 | Dividend Yield | — |
| Payout | 0.00% | Employees | 677 | IPO | — |
| P/E | 18.20 | Forward P/E | 16.65 | PEG | — |
| P/S | 7.64 | P/B | 8.65 | P/C | — |
| EV/EBITDA | 21.23 | EV/Sales | 7.61 | Quick Ratio | 3.52 |
| Current Ratio | 7.13 | Debt/Eq | 19.28 | LT Debt/Eq | — |
| EPS (ttm) | 0.86 | EPS next Y | 0.94 | EPS Growth | -0.00% |
| Revenue Growth | 12.00% | Earnings | 2026-02-25 | ROA | 21.76% |
| ROE | 63.17% | ROIC | — | Gross Margin | 54.71% |
| Oper. Margin | 38.01% | Profit Margin | 42.87% | Shs Outstand | 238.00M |
| Shs Float | 233.24M | Short Float | 10.03% | Short Ratio | 8.33 |
| Short Interest | — | 52W High | 25.67 | 52W Low | 13.50 |
| Beta | 0.48 | Avg Volume | 2.38M | Volume | 1.04M |
| Target Price | $25.67 | Recom | None | Prev Close | $15.52 |
| Price | $15.65 | Change | 0.84% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.67
Mean price target
2. Current target
$15.65
Latest analyst target
3. DCF / Fair value
$0.22
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.65
Low
$17.00
High
$30.00
Mean
$25.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-08 | main | Raymond James | Strong Buy → Strong Buy | $32 |
| 2025-03-04 | reit | Cantor Fitzgerald | Overweight → Overweight | $25 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-11-08 | main | Raymond James | Strong Buy → Strong Buy | $25 |
| 2024-10-14 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-09-20 | reit | Cantor Fitzgerald | Overweight → Overweight | $20 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-08-09 | main | Cantor Fitzgerald | Overweight → Overweight | $20 |
| 2024-07-09 | main | Cantor Fitzgerald | Overweight → Overweight | $15 |
| 2024-06-20 | main | Mizuho | Buy → Buy | $14 |
| 2024-05-10 | main | Raymond James | Strong Buy → Strong Buy | $10 |
| 2024-05-10 | main | Cantor Fitzgerald | Overweight → Overweight | $10 |
| 2024-05-10 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-10 | main | Mizuho | Buy → Buy | $12 |
| 2024-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-03-01 | main | Mizuho | Buy → Buy | $10 |
| 2024-02-29 | main | Cantor Fitzgerald | Overweight → Overweight | $8 |
| 2024-02-29 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-01-22 | main | Mizuho | Buy → Buy | $9 |
| 2024-01-09 | main | HC Wainwright & Co. | Buy → Buy | $6 |
- Will ADMA’s (ADMA) Q4 2025 Earnings and Profit Focus Quiet Skeptics of Its Business Model? - simplywall.st Wed, 25 Feb 2026 10
- ADMA Biologics earnings up next: Can momentum match lofty targets? - Investing.com Wed, 25 Feb 2026 16
- ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With A 59.42% Potential Upside - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note - Yahoo Finance hu, 19 Feb 2026 22
- Preview: ADMA Biologics's Earnings - Benzinga ue, 24 Feb 2026 16
- ADMA Biologics to Announce Q4 Earnings on February 25 - Intellectia AI ue, 24 Feb 2026 23
- The Play On ADMA Biologics: A Discounted Stock With Good Prospects (NASDAQ:ADMA) - Seeking Alpha Fri, 12 Dec 2025 08
- ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Quiver Quantitative Wed, 18 Feb 2026 12
- Is ADMA Biologics (ADMA) Pricing Reflecting Its Multi Year Share Price Surge? - simplywall.st hu, 19 Feb 2026 17
- ADMA Biologics Inc (ADMA) Stock Analysis: Unlocking a 59.52% Upside in the Biotech Arena - DirectorsTalk Interviews ue, 17 Feb 2026 11
- ADMA Biologics CEO Sale And Options Activity Versus Valuation And Momentum - Yahoo Finance Wed, 18 Feb 2026 21
- Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance Fri, 12 Dec 2025 08
- Is ADMA Biologics (ADMA) Still Attractive After Recent Share Price Pullback - Yahoo Finance Mon, 12 Jan 2026 08
- ADMA Biologics Inc (ADMA) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance hu, 30 Oct 2025 07
- Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance hu, 19 Feb 2026 17
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 21000 | 337680 | — | Sale at price 16.08 per share. | GROSSMAN ADAM S | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 15000 | 81000 | — | Conversion of Exercise of derivative security at price 5.40 per share. | GROSSMAN ADAM S | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | GROSSMAN JERROLD B | Director | — | 2026-02-09 00:00:00 | D |
| 3 | 282529 | — | — | Stock Award(Grant) at price 0.00 per share. | GROSSMAN ADAM S | Chief Executive Officer | — | 2026-02-09 00:00:00 | D |
| 4 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | GUIHEEN LAWRENCE P | Director | — | 2026-02-09 00:00:00 | D |
| 5 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | FINGER ALISON CECILY | Director | — | 2026-02-09 00:00:00 | D |
| 6 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | KWON YOUNG T. PH.D. | Director | — | 2026-02-09 00:00:00 | D |
| 7 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | ELMS STEVEN A | Director | — | 2026-02-09 00:00:00 | D |
| 8 | 10690 | — | — | Stock Award(Grant) at price 0.00 per share. | SALAS EDUARDO RENE | Director | — | 2026-02-09 00:00:00 | D |
| 9 | 91631 | — | — | Stock Award(Grant) at price 0.00 per share. | KESTENBERG-MESSINA KAITLIN M. | Officer | — | 2026-02-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -261.03K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 148.93M | 31.29M | -32.84M | -53.09M |
| TotalUnusualItems | -1.24M | -26.17M | -6.67M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -1.24M | -26.17M | -6.67M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | 197.67M | -28.24M | -65.90M | -71.65M |
| ReconciledDepreciation | 8.04M | 8.33M | 7.11M | 5.50M |
| ReconciledCostOfRevenue | 199.24M | 161.66M | 112.42M | 74.99M |
| EBITDA | 147.69M | 5.12M | -39.51M | -53.09M |
| EBIT | 139.64M | -3.21M | -46.62M | -58.59M |
| NetInterestIncome | -11.83M | -23.41M | -19.23M | -13.02M |
| InterestExpense | 13.93M | 25.03M | 19.28M | 13.06M |
| InterestIncome | 2.10M | 1.62M | 45.00K | 35.00K |
| NormalizedIncome | 198.65M | -2.06M | -59.23M | -71.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 197.67M | -28.24M | -65.90M | -71.65M |
| TotalExpenses | 287.47M | 236.58M | 193.44M | 139.32M |
| TotalOperatingIncomeAsReported | 138.98M | 21.63M | -39.37M | -58.37M |
| DilutedAverageShares | 243.34M | 223.98M | 197.87M | 139.58M |
| BasicAverageShares | 233.08M | 223.98M | 197.87M | 139.58M |
| DilutedEPS | 0.81 | -0.13 | -0.33 | -0.51 |
| BasicEPS | 0.85 | -0.13 | -0.33 | -0.51 |
| DilutedNIAvailtoComStockholders | 197.67M | -28.24M | -65.90M | -71.65M |
| NetIncomeCommonStockholders | 197.67M | -28.24M | -65.90M | -71.65M |
| NetIncome | 197.67M | -28.24M | -65.90M | -71.65M |
| NetIncomeIncludingNoncontrollingInterests | 197.67M | -28.24M | -65.90M | -71.65M |
| NetIncomeContinuousOperations | 197.67M | -28.24M | -65.90M | -71.65M |
| TaxProvision | -71.96M | 0.00 | 0.00 | |
| PretaxIncome | 125.71M | -28.24M | -65.90M | -71.65M |
| OtherIncomeExpense | -1.44M | -26.46M | -7.30M | -252.00K |
| OtherNonOperatingIncomeExpenses | -193.00K | -287.00K | -635.00K | -252.00K |
| SpecialIncomeCharges | -1.24M | -26.17M | -6.67M | 0.00 |
| OtherSpecialCharges | 1.24M | 26.17M | 6.67M | |
| NetNonOperatingInterestIncomeExpense | -11.83M | -23.41M | -19.23M | -13.02M |
| InterestExpenseNonOperating | 13.93M | 25.03M | 19.28M | 13.06M |
| InterestIncomeNonOperating | 2.10M | 1.62M | 45.00K | 35.00K |
| OperatingIncome | 138.98M | 21.63M | -39.37M | -58.37M |
| OperatingExpense | 80.57M | 67.31M | 74.63M | 59.55M |
| OtherOperatingExpenses | 4.25M | 4.27M | 17.84M | 12.29M |
| DepreciationAmortizationDepletionIncomeStatement | 388.00K | 724.00K | 715.00K | 715.00K |
| DepreciationAndAmortizationInIncomeStatement | 388.00K | 724.00K | 715.00K | 715.00K |
| Amortization | 388.00K | 724.00K | 715.00K | 715.00K |
| AmortizationOfIntangiblesIncomeStatement | 388.00K | 724.00K | 715.00K | 715.00K |
| ResearchAndDevelopment | 1.81M | 3.30M | 3.61M | 3.65M |
| SellingGeneralAndAdministration | 74.12M | 59.02M | 52.46M | 42.90M |
| GrossProfit | 219.55M | 88.94M | 35.27M | 1.17M |
| CostOfRevenue | 206.90M | 169.27M | 118.81M | 79.77M |
| TotalRevenue | 426.45M | 258.21M | 154.08M | 80.94M |
| OperatingRevenue | 426.45M | 258.21M | 154.08M | 80.94M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 236.62M | 226.06M | 221.82M | 195.81M |
| ShareIssued | 236.62M | 226.06M | 221.82M | 195.81M |
| NetDebt | 79.24M | 56.31M | 43.78M | |
| TotalDebt | 82.12M | 141.42M | 154.44M | 102.92M |
| TangibleBookValue | 345.03M | 131.18M | 147.43M | 135.91M |
| InvestedCapital | 421.36M | 265.80M | 294.81M | 236.04M |
| WorkingCapital | 275.87M | 207.21M | 231.13M | 178.35M |
| NetTangibleAssets | 345.03M | 131.18M | 147.43M | 135.91M |
| CapitalLeaseObligations | 9.78M | 10.82M | 11.61M | 8.05M |
| CommonStockEquity | 349.02M | 135.21M | 151.97M | 141.17M |
| TotalCapitalization | 421.36M | 265.80M | 294.81M | 236.04M |
| TotalEquityGrossMinorityInterest | 349.02M | 135.21M | 151.97M | 141.17M |
| StockholdersEquity | 349.02M | 135.21M | 151.97M | 141.17M |
| RetainedEarnings | -308.58M | -506.26M | -478.02M | -412.11M |
| AdditionalPaidInCapital | 657.58M | 641.44M | 629.97M | 553.27M |
| CapitalStock | 24.00K | 23.00K | 22.00K | 19.58K |
| CommonStock | 24.00K | 23.00K | 22.00K | 19.58K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 139.66M | 193.98M | 196.49M | 135.08M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 84.12M | 144.17M | 157.22M | 104.70M |
| OtherNonCurrentLiabilities | 1.67M | 2.11M | 1.85M | 397.35K |
| NonCurrentDeferredLiabilities | 1.55M | 1.69M | 1.83M | 1.98M |
| NonCurrentDeferredRevenue | 1.55M | 1.69M | 1.83M | 1.98M |
| LongTermDebtAndCapitalLeaseObligation | 80.90M | 140.37M | 153.54M | 102.33M |
| LongTermCapitalLeaseObligation | 8.56M | 9.78M | 10.70M | 7.46M |
| LongTermDebt | 72.34M | 130.59M | 142.83M | 94.87M |
| CurrentLiabilities | 55.54M | 49.81M | 39.27M | 30.38M |
| OtherCurrentLiabilities | 1.85M | 2.37M | 1.80M | 1.01M |
| CurrentDeferredLiabilities | 143.00K | 182.00K | 143.00K | 142.83K |
| CurrentDeferredRevenue | 143.00K | 182.00K | 143.00K | 142.83K |
| CurrentDebtAndCapitalLeaseObligation | 1.22M | 1.04M | 905.00K | 591.08K |
| CurrentCapitalLeaseObligation | 1.22M | 1.04M | 905.00K | 591.08K |
| PayablesAndAccruedExpenses | 52.33M | 46.21M | 36.42M | 28.63M |
| CurrentAccruedExpenses | 28.63M | 30.55M | 23.19M | 16.20M |
| InterestPayable | 2.86M | 546.00K | ||
| Payables | 23.70M | 15.66M | 13.23M | 12.43M |
| TotalTaxPayable | 3.48M | 0.00 | ||
| IncomeTaxPayable | 3.48M | 0.00 | ||
| AccountsPayable | 20.22M | 15.66M | 13.23M | 12.43M |
| TotalAssets | 488.68M | 329.18M | 348.46M | 276.25M |
| TotalNonCurrentAssets | 157.27M | 72.17M | 78.06M | 67.52M |
| OtherNonCurrentAssets | 5.66M | 4.67M | 4.77M | 4.07M |
| NonCurrentPrepaidAssets | 4.07M | |||
| NonCurrentDeferredAssets | 84.28M | 0.00 | ||
| NonCurrentDeferredTaxesAssets | 84.28M | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 3.99M | 4.03M | 4.54M | 5.26M |
| OtherIntangibleAssets | 460.00K | 499.00K | 1.01M | 1.73M |
| Goodwill | 3.53M | 3.53M | 3.53M | 3.53M |
| NetPPE | 63.34M | 63.47M | 68.75M | 58.20M |
| AccumulatedDepreciation | -33.55M | -26.74M | -19.48M | -13.27M |
| GrossPPE | 96.89M | 90.21M | 88.22M | 71.47M |
| Leases | 21.07M | 20.81M | 17.93M | 11.13M |
| ConstructionInProgress | 8.15M | 2.27M | 6.73M | 5.50M |
| OtherProperties | 29.94M | 30.73M | 29.25M | 23.97M |
| MachineryFurnitureEquipment | 11.61M | 11.84M | 10.43M | 7.47M |
| BuildingsAndImprovements | 21.79M | 20.22M | 19.54M | 19.07M |
| LandAndImprovements | 4.34M | 4.34M | 4.34M | 4.34M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 331.41M | 257.01M | 270.40M | 208.73M |
| OtherCurrentAssets | 8.03M | 5.33M | 5.09M | 4.34M |
| PrepaidAssets | 4.34M | |||
| Inventory | 170.24M | 172.91M | 163.28M | 124.72M |
| FinishedGoods | 48.12M | 70.29M | 58.47M | 29.00M |
| WorkInProcess | 61.64M | 49.62M | 56.17M | 58.97M |
| RawMaterials | 60.47M | 53.00M | 48.64M | 36.76M |
| Receivables | 50.00M | 27.42M | 15.51M | 28.58M |
| AccountsReceivable | 50.00M | 27.42M | 15.51M | 28.58M |
| AllowanceForDoubtfulAccountsReceivable | -200.00K | -100.00K | -100.00K | -200.00K |
| GrossAccountsReceivable | 50.20M | 27.52M | 15.61M | 28.78M |
| CashCashEquivalentsAndShortTermInvestments | 103.15M | 51.35M | 86.52M | 51.09M |
| CashAndCashEquivalents | 103.15M | 51.35M | 86.52M | 51.09M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 110.10M | 3.82M | -73.42M | -125.88M |
| RepaymentOfDebt | -60.00M | -158.60M | -100.04M | -34.00K |
| IssuanceOfDebt | 0.00 | 135.00M | 151.75M | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 64.64M | 121.14M |
| CapitalExpenditure | -8.57M | -4.98M | -13.91M | -13.51M |
| InterestPaidSupplementalData | 10.67M | 18.05M | 13.88M | 11.16M |
| IncomeTaxPaidSupplementalData | 9.39M | 0.00 | 0.00 | |
| EndCashPosition | 103.15M | 51.35M | 86.52M | 51.09M |
| BeginningCashPosition | 51.35M | 86.52M | 51.09M | 55.92M |
| ChangesInCash | 51.80M | -35.17M | 35.43M | -4.83M |
| FinancingCashFlow | -58.30M | -38.99M | 108.85M | 121.05M |
| CashFlowFromContinuingFinancingActivities | -58.30M | -38.99M | 108.85M | 121.05M |
| NetOtherFinancingCharges | -5.80M | -16.49M | -7.68M | -62.00K |
| ProceedsFromStockOptionExercised | 7.49M | 1.10M | 175.00K | 0.00 |
| NetCommonStockIssuance | 0.00 | 0.00 | 64.64M | 121.14M |
| CommonStockIssuance | 0.00 | 0.00 | 64.64M | 121.14M |
| NetIssuancePaymentsOfDebt | -60.00M | -23.60M | 51.71M | -34.00K |
| NetLongTermDebtIssuance | -60.00M | -23.60M | 51.71M | -34.00K |
| LongTermDebtPayments | -60.00M | -158.60M | -100.04M | -34.00K |
| LongTermDebtIssuance | 0.00 | 135.00M | 151.75M | 0.00 |
| InvestingCashFlow | -8.57M | -4.98M | -13.91M | -13.51M |
| CashFlowFromContinuingInvestingActivities | -8.57M | -4.98M | -13.91M | -13.51M |
| NetIntangiblesPurchaseAndSale | -349.00K | -210.00K | 0.00 | 0.00 |
| PurchaseOfIntangibles | -349.00K | -210.00K | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -8.23M | -4.77M | -13.91M | -13.51M |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -8.23M | -4.77M | -13.91M | -13.51M |
| OperatingCashFlow | 118.67M | 8.80M | -59.51M | -112.37M |
| CashFlowFromContinuingOperatingActivities | 118.67M | 8.80M | -59.51M | -112.37M |
| ChangeInWorkingCapital | -18.54M | -10.12M | -18.29M | -51.68M |
| ChangeInOtherCurrentLiabilities | -1.14M | -791.00K | -502.00K | 219.00K |
| ChangeInPayablesAndAccruedExpense | 5.19M | 11.37M | 8.33M | 9.70M |
| ChangeInAccruedExpense | 1.04M | 7.53M | 7.53M | 8.34M |
| ChangeInPayable | 4.15M | 3.84M | 800.00K | 1.36M |
| ChangeInAccountPayable | 4.15M | 3.84M | 800.00K | 1.36M |
| ChangeInPrepaidAssets | -2.68M | 841.00K | -634.00K | -3.07M |
| ChangeInInventory | 2.67M | -9.63M | -38.56M | -43.19M |
| ChangeInReceivables | -22.58M | -11.92M | 13.07M | -15.34M |
| ChangesInAccountReceivables | -22.58M | -11.92M | 13.07M | -15.34M |
| OtherNonCashItems | 808.00K | 6.29M | 5.26M | 1.75M |
| StockBasedCompensation | 13.62M | 6.19M | 5.21M | 3.49M |
| DeferredTax | -84.28M | 0.00 | 0.00 | |
| DeferredIncomeTax | -84.28M | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 8.04M | 8.33M | 7.11M | 5.50M |
| DepreciationAndAmortization | 8.04M | 8.33M | 7.11M | 5.50M |
| OperatingGainsLosses | 1.35M | 26.36M | 7.10M | 221.00K |
| GainLossOnSaleOfPPE | 106.00K | 182.00K | 427.00K | 221.00K |
| NetIncomeFromContinuingOperations | 197.67M | -28.24M | -65.90M | -71.65M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ADMA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|